BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Decrease in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 254,200 shares, a decrease of 39.1% from the August 15th total of 417,200 shares. Based on an average daily volume of 2,930,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.7% of the shares of the company are short sold.

Institutional Investors Weigh In On BriaCell Therapeutics

Large investors have recently made changes to their positions in the company. Onyx Bridge Wealth Group LLC raised its stake in shares of BriaCell Therapeutics by 66.7% during the first quarter. Onyx Bridge Wealth Group LLC now owns 50,000 shares of the company’s stock valued at $143,000 after purchasing an additional 20,000 shares in the last quarter. K.J. Harrison & Partners Inc raised its position in shares of BriaCell Therapeutics by 7.8% during the 1st quarter. K.J. Harrison & Partners Inc now owns 87,044 shares of the company’s stock worth $249,000 after buying an additional 6,329 shares in the last quarter. Finally, National Bank of Canada FI lifted its stake in shares of BriaCell Therapeutics by 200.0% in the 4th quarter. National Bank of Canada FI now owns 7,500 shares of the company’s stock worth $40,000 after acquiring an additional 5,000 shares during the period. Institutional investors and hedge funds own 15.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of BriaCell Therapeutics in a report on Wednesday.

BriaCell Therapeutics Price Performance

NASDAQ:BCTX traded down $0.07 during midday trading on Friday, reaching $0.56. 3,172,324 shares of the company traded hands, compared to its average volume of 1,204,289. BriaCell Therapeutics has a twelve month low of $0.52 and a twelve month high of $6.38. The company has a fifty day moving average price of $0.74 and a 200 day moving average price of $1.60. The firm has a market capitalization of $10.25 million, a price-to-earnings ratio of -0.45 and a beta of 1.31.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Friday, June 14th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.66. On average, equities research analysts forecast that BriaCell Therapeutics will post -1.39 earnings per share for the current fiscal year.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.